Literature DB >> 21813205

Mycobacterium tuberculosis: immune evasion, latency and reactivation.

Antima Gupta1, Akshay Kaul, Anthony G Tsolaki, Uday Kishore, Sanjib Bhakta.   

Abstract

One-third of the global human population harbours Mycobacterium tuberculosis in dormant form. This dormant or latent infection presents a major challenge for global efforts to eradicate tuberculosis, because it is a vast reservoir of potential reactivation and transmission. This article explains how the pathogen evades the host immune response to establish a latent infection, and how it emerges from a state of latency to cause reactivation disease. This review highlights the key factors responsible for immune evasion and reactivation. It concludes by identifying interesting candidates for drug or vaccine development, as well as identifying unresolved questions for the future research.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813205     DOI: 10.1016/j.imbio.2011.07.008

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  55 in total

1.  Mycobacterial induction of autophagy varies by species and occurs independently of mammalian target of rapamycin inhibition.

Authors:  Alfred J Zullo; Sunhee Lee
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

2.  Mycobacterium tuberculosis pellicles express unique proteins recognized by the host humoral response.

Authors:  Patrick W Kerns; David F Ackhart; Randall J Basaraba; Jeff G Leid; Mark E Shirtliff
Journal:  Pathog Dis       Date:  2014-02-26       Impact factor: 3.166

Review 3.  Manipulation of the mononuclear phagocyte system by Mycobacterium tuberculosis.

Authors:  Geanncarlo Lugo-Villarino; Olivier Neyrolles
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-21       Impact factor: 6.915

4.  The proprotein convertase subtilisin/kexin furinA regulates zebrafish host response against Mycobacterium marinum.

Authors:  Markus J T Ojanen; Hannu Turpeinen; Zuzet M Cordova; Milka M Hammarén; Sanna-Kaisa E Harjula; Mataleena Parikka; Mika Rämet; Marko Pesu
Journal:  Infect Immun       Date:  2015-01-26       Impact factor: 3.441

5.  A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium Tuberculosis.

Authors:  Kaitlyn Schaaf; Virginia Hayley; Alexander Speer; Frank Wolschendorf; Michael Niederweis; Olaf Kutsch; Jim Sun
Journal:  Assay Drug Dev Technol       Date:  2016-06-21       Impact factor: 1.738

Review 6.  Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

Authors:  Satria A Prabowo; Matthias I Gröschel; Ed D L Schmidt; Alena Skrahina; Traian Mihaescu; Serap Hastürk; Rotislav Mitrofanov; Edita Pimkina; Ildikó Visontai; Bouke de Jong; John L Stanford; Père-Joan Cardona; Stefan H E Kaufmann; Tjip S van der Werf
Journal:  Med Microbiol Immunol       Date:  2012-11-10       Impact factor: 3.402

7.  Mycobacterium marinum down-regulates miR-148a in macrophages in an EsxA-dependent manner.

Authors:  Haichong Wu; Yanqing Bao; Lin Wang; Xiujun Li; Jianjun Sun
Journal:  Int Immunopharmacol       Date:  2019-05-09       Impact factor: 4.932

Review 8.  Influence of diabetes mellitus on immunity to human tuberculosis.

Authors:  Pavan Kumar Nathella; Subash Babu
Journal:  Immunology       Date:  2017-06-29       Impact factor: 7.397

Review 9.  Disruption of immune regulation by microbial pathogens and resulting chronic inflammation.

Authors:  Kenneth Barth; Daniel G Remick; Caroline A Genco
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

10.  Differential trafficking of TLR1 I602S underlies host protection against pathogenic mycobacteria.

Authors:  Bryan E Hart; Richard I Tapping
Journal:  J Immunol       Date:  2012-10-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.